塞瑞替尼 Ceritinib Ceritinib, also known as LDK378, is a selective inhibitor of ALK1, a target found in metastatic non-small cell lung cancer (NSCLC).
更新時(shí)間:2023-07-12
廠商性質(zhì):代理商
布格替尼 Brigatinib Brigatinib, also known as AP-26113, is an orally active, potent and selective Dual ALK/EGFR inhibitor.
更新時(shí)間:2023-07-12
廠商性質(zhì):代理商
艾樂替尼 Alectinib Alectinib, also known as AF802, or CH5424802 or RO5424802, is a potent, selective, and orally available ALK inhibitor with a unique chemical scaffold
更新時(shí)間:2023-07-12
廠商性質(zhì):代理商
瑞格非尼 Regorafenib Regorafenib, also known as BAY 73-4506 ; is an orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities.
更新時(shí)間:2023-07-12
廠商性質(zhì):代理商
舒尼替尼 Sunitinib It is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor. Sunitinib malate salt was approved by the FDA for the treatment of renal cell carcinoma.
更新時(shí)間:2023-07-12
廠商性質(zhì):代理商